

Speakers



Dr Gunther Bechmann
Pfizer



Dr Andreas Flückiger
Formerly
F. Hoffmann-La Roche



Dr Filipe Gaspar
Hovione



Frank Lehman
Skan



Dr Morcos Loka
Minapharm



Dr Rainer Nicolai
F. Hoffmann-La Roche



Julian Petersen
groninger



Vimal Sachdeva
WHO



Robert G. Schwarz
FH Campus, Vienna



Dr Harald Stahl
GEA



Dr Christoph Umbricht
Lonza



Fred Wulfgramm
Merz Pharma

Handling of Highly Active Products

Part of PharmaCongress 2023

28/29 March 2023 | Wiesbaden, Germany



State-of-the-art Continuous Tableting equipment, Hovione Sete Casas, Portugal

Highlights

- Case Study Pfizer: Construction of an OEB 4 Manufacturing Site
- Case Study Lonza: SU Equipment in the Commercial Manufacture of ADCs
- Case Study Minapharm: Design of a HPAPI Biomanufacturing Facility
- Case Study F. Hoffmann-La Roche: Handling of Solids with Single-Use Systems
- Case Study Merz: Production of sterile & highly potent Products
- Managing Occupational Health Risks in Potent Compound Handling
- New Approach for assessing the Performance of High-Containment Systems
- Technical Possibilities for contained Product Handling
- GMP Inspection Experience of Products containing Hazardous Substances
- New EU GMP Annex I: Cross Contamination Control Strategy

Objectives

Main focus of this conference is on the connection of cGMPs with safety aspects, especially on avoiding cross contamination and minimizing exposure. Recently completed projects and facilities for the production of highly potent products demonstrate the state of the art.

It will also deal with exposure & cleaning validation limits and the possibilities offered by containment technology, shown by real life examples from pharmaceutical industry including oral solid dosage forms and sterile medicinal products.

Background

Exposure to active pharmaceutical ingredients must be kept within acceptable limits. The protection of employees must be achieved primarily by technical measures and not through personal protective equipment. Several containment solutions like glove boxes, isolators, special valves and transfer ports are available. This equipment has to fit to the surrounding, the product requirements and the organisational circumstances. Therefore detailed planning is necessary.

But GMP also has requirements for contamination or the avoidance of contamination / cross contamination as far as possible (see chapters 3 (Premises & Equipment) and 5 (Production) of the EU GMP Guidelines. By introducing the PDE concept (Permitted Daily Exposure) by the European Medicines Agency, occupational medicine and GMP requirements are now based on the same scientific basis, namely on the question: how much exposure is uncritical for a person (whether patient or employee)? This important question has to be answered for both, dedicated and multipurpose equipment.

And since the new Annex 1 also requires measures against cross contamination, this is also becoming increasingly relevant for sterile products. And all the more so, the more potent the starting materials or products are. How can a cross contamination control strategy look like and how is it documented?

Learn from recently finished projects and see how the state-of-the-art looks like. This applies to oral solid forms as well as to liquid, sterile medicinal products.

Target Audience

This conference aims at persons from production, engineering and quality, responsible for

- Design of new manufacturing areas
- Operation of processes containing highly potent material
- Occupational safety
- Cleaning concepts and contamination prevention

as well as engineering and plant-construction companies working in containment projects.

Moderator

Dr Harald Stahl, GEA

Programme 28 March 2023

Principles of Assessing and Managing Occupational Health Risks in Potent Compound Handling

Dr Andreas Flückiger, formerly F. Hoffmann-La Roche

- Legal requirements regarding worker safety
- Assessing the hazard: potency and toxicity of the compounds. Occupational exposure limits and exposure bands
- Ensuring the right level of process containment: Design exposure limits as drivers for equipment selection. The illusion of "closed processes".
- Setting of health-based exposure limits and process containment: great benefits for GMP

Exposures to pharmaceuticals at the workplace must be controlled to below acceptable limits. For most APIs, the manufacturer himself needs to develop these limits, and compliance with them must be documented. Protection of the workers from overexposure must be achieved primarily by technical means and not by means of personal protective equipment. Equipment must have adequate containment so that the required exposure control is ensured at least in all routine situations. Existing facilities must be upgraded accordingly. The toxicological and pharmacological basis of assessing APIs with the objective of worker protection is the same as the one justifying GMP cleaning criteria and acceptance of multi-product use of a facility. Primary process containment is the key tool for the prevention of airborne cross-contamination and via the one by mechanical transfer.

Review of technical Requirements for contained Product Handling

Dr Harald Stahl, GEA

- Product transfer- review of current possibilities
- Sampling 1 - Review of possibilities for contained sampling
- Sampling 2 - Examples for in-line measurements allowing to drop sampling
- Cleaning: Examples of automatic cleaning

Case Study Pfizer: Constructional and regulatory Challenges of an OEB 4 Manufacturing Site (online)

Dr Gunther Bechmann, Pfizer

Special requirements have to be considered for planning and construction of buildings intended for manufacture of highly potent medicinal products

- Implementation of special GMP Requirements
- Special staff training
- Environmental aspects

GMP Inspection Experience of Products containing hazardous Substances & Introduction to WHO's Prequalification Program

Vimal Sachdeva, WHO

- WHO Prequalification (PQ) history and process
- WHO PQ of pharmaceutical products containing hazardous substances
- GMP-compliant handling of hazardous substances
- Challenges during GMP inspections

Case Study Hovione: Spray Drying and Continuous Tableting of highly active Materials

Dr Filipe Gaspar, Hovione

- Relevance of Spray Drying and Continuous Tableting in the Pharmaceutical Industry
- From risk assessment to lab development and to commercial manufacturing
- Specific requirements for Spray Drying and Continuous Tableting
- Examples of lab to commercial units capable of handling potent APIs

Programme 29 March 2023

Cross Contamination Control Strategy in Light of the new Annex I

Robert G. Schwarz, FH Campus, Vienna

- OHS-requirements and CCS according new Annex 1
- Cross Contamination Control - the unseen stepchild of them with maybe a high potent habit
- How to implement a compliant CCS with Containment requirements properly
- "Close, closer, isolator - but what about RABS?" - Question from the desperate pharmacies

Case Study Lonza: Use of single-use equipment for the commercial production of highly potent ADCs

Dr Christoph Umbricht, Lonza

- Challenges in the production of ADCs (Antibody drug conjugates)
 - GMP aspects
 - Personal safety
- Current challenges in the use of single use components in the pharmaceutical industry
 - Multisourcing
 - Qualification of single-use materials
- A look into the future: Single-use equipment in ADC production

Case Study Minapharm: Design of a HPAPI Biomanufacturing Facility

Dr Morcos Loka, Minapharm

- How to apply risk management in the design of a facility for biopharmaceutical HPAPIs
- How to achieve compliance with US & EU GMP and EHS requirements
- What controls can be applied regarding equipment closure, flow of materials and personnel, waste management, cleanroom, HVAC
- How to set a suitable containment strategy
- What are the possible challenges and how to overcome
- How to quantitatively evaluate the effectiveness of these controls

Case Study Merz: Production of sterile & highly potent Products

Fred Wulfgramm, Merz

Julian Petersen, Groninger

Frank Lehman, Skan

Handling of Solids with Single-Use Systems in the chemical Synthesis of highly active Substances

Dr Rainer Nicolai, F. Hoffmann-La Roche

- Available Equipment & Technology
- Pros and Cons of Single-Use Systems
- Case Studies: Experience with SUT in chemical synthesis of highly active substances

New Approach for assessing Dust-Retention Performance of high-containment Systems

Dr Andreas Flückiger, formerly F. Hoffmann-La Roche

- Continuous or periodic dust emission monitoring. Results in $\mu\text{g}/\text{m}^3$.
- Early detection of otherwise unnoticed leakage
- Intervention before worker exposures become too high

High containment systems have generally been tested for their containment performance, for example based on ISPE's "SME-PAC" guide. This reflects the design and performance of the equipment as it leaves the factory of its manufacturer. Over time, these systems may lose some of their containment capability, and this is often not visible to the naked eye. The Digital Canary is a system to continuously or periodically monitor dust emissions with the objective to detect leakage before it becomes critical for worker safety. Contrary to a particle counter, it delivers the results in $\mu\text{g}/\text{m}^3$. The results can serve as a trigger for preventive maintenance and can replace costly substance-specific industrial hygiene sampling. The system is compatible with a range of solid dosage applications. The Digital Canary is being developed for additional uses.

Speakers

Speakers



Dr Gunther Bechmann, Pfizer

Gunther Bechmann is a Pharmacist and since 2005 employee of Pfizer in different leading positions.



**Dr Andreas Flückiger
Formerly F. Hoffmann-La Roche**

An occupational physician by training, Andreas Flückiger has been the head of the occupational health services of the Roche Group for 30 years.

He is active in leading roles in numerous national and international associations such as the International Association for Occupational and Environmental Health in the Chemical Industry (Medichem), in the Scientific Committee of the European Council for Ecotoxicology and Toxicology of Chemicals (ECETOC).



Dr Filipe Gaspar, Hovione

Vice President, Technology Intensification.



**Frank Lehman
Skan**

Head Strategic Product Management .



Dr Morcos Loka, Minapharm

Dr Morcos Loka is Training Manager & GMP Advisor at Minapharm, Cairo, Egypt. He has over 20 years of experience in the pharmaceutical & biopharmaceutical industry including manufacture

of sterile and non-sterile products, handling and conduction of of audits, GMP training, QRM studies including manufacturing of HPAPIs in shared facilities and design of pharmaceutical and biopharmaceutical manufacturing facilities. He also has a Master in Business Administration (MBA), B.Sc. (Hons) in Pharmaceutical Sciences.



**Dr Rainer Nicolai
F. Hoffmann-La Roche**

Dr Nicolai has been involved in the handling of high purity and high activity substances since 1998. With a total of 15 years of experience as a project manager and containment expert at Roche, he is involved in a wide range of issues with high practical relevance.



**Julian Petersen,
groninger**

Director of Business Development and Product Management.



Vimal Sachdeva, WHO

Vimal Sachdeva, based in Geneva, Switzerland, has been working with the WHO PQ program as a Senior GMP inspector since October 2020. Prior to joining WHO, he worked as a Senior GMP Auditor with Singapore's Health Sciences Authority.



Robert G. Schwarz, FH Campus, Vienna
 Robert Schwarz, graduate in “Bioprocess Engineering” and “Biotechnological Quality Management”, was responsible for environmental monitoring as well as validation of decontamination systems at Baxter (now Shire). Since 2010 he is working as a lecturer in the field of biotechnology with a focus on validation/qualification, aseptic process methods and cleanroom technology at the University of Applied Sciences Vienna.



Dr Harald Stahl, GEA
 Dr Harald Stahl worked in the Pharmaceutical Development of Schering AG in Germany. At that time his main interest was the aseptic production of pellets. Since 1995 he served within GEA Process Technology in various positions. Presently he owns the position of a Group Director Application & Strategy Management of GEA. He has published more than 20 papers on various aspects of pharmaceutical production.



**Dr Christoph Umbricht
 Lonza**
 Christoph Umbricht studied molecular biology and genetics and is group leader of a production facility for antibody-drug conjugates (ADCs) at Lonza in Visp, Switzerland. His team is responsible for the commercial production of ADCs.



Fred Wulfgramm, Merz Pharma
 Fred Wulfgramm has a wealth of experience in Engineering in clean room industries. He has worked in this capacity for different Companies in the Pharma, Cosmetics and Food Industries in a lot of roles. Today he is Head of Engineering at the Merz Pharma Site in Dessau.

PharmaCongress 2023



The guiding theme of the PharmaCongress 2023 on 28/29 March will be „users sharing challenges and solutions in practice“. Therefore, benefit from your colleagues' experience and from the direct information exchange at PharmaCongress & PharmaTechnica 2023.

The Tracks

As a participant you can switch between any of the tracks any time and also visit the PharmaTechnica Expo with more than 100 international exhibitors.

Conference Tracks	28 Mar	29 Mar
European Aseptic Conference	✓	✓
New Developments in Barrier Systems & Robotics	✓	✓
PUPSIT: Complying with the Main Annex 1 Changes	✓	✓
GMP for Pre-Filled Syringes (PFS)	✓	✓
Pharma 4.0 & Digitalisation	✓	✓
Handling of Highly Active Products	✓	✓
ATMP – Manufacturing, Quality & Safety	✓	✓
PharmaTechnica Expo	✓	✓

Find out more about the other conference tracks on our website www.pharma-congress.com.

Reservation Form (Please complete in full)

Handing of Highly Active Products - Part of PharmaCongress 2023, 28/29 March 2023, Wiesbaden, Germany

- Day 1 & 2 (28/29 March 2023)
- Day 1 (28 March 2023)
- Day 2 (29 March 2023)
- Yes, I would also like to take part in the Social Event on the evening of 28 March 2023.

Title, first name, surname

Department

Company

Important: Please indicate your company's VAT ID Number

Purchase Order Number, if applicable

City

ZIP Code

Country

Phone / Fax

E-Mail (Please fill in)

CONCEPT HEIDELBERG
P.O. Box 101764
Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg
GERMANY

If the bill-to-address deviates from the specifications on the right, please fill out here:

General terms and conditions

- If you cannot attend the conference you have two options:
- 1. We are happy to welcome a substitute colleague at any time.
- 2. If you have to cancel entirely we must charge the following processing fees:
 - Cancellation until 4 weeks prior to the conference 10 %
 - Cancellation until 3 weeks prior to the conference 25 %
 - Cancellation until 2 weeks prior to the conference 50 %
 - Cancellation within 2 weeks prior to the conference 100 %.

- CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.
- Terms of payment: Payable without deductions within 10 days after receipt of invoice.
- Important: This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message.
- In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed!) (As of July 2022).
- German law shall apply. Court of jurisdiction is Heidelberg.

- Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html).
- I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

Date of the Conference

Tuesday, 28 March 2023, 09.00 - 18.00 h
Wednesday, 29 March 2023, 09.00 - 17.00 h
Registration: 28/29 March 2023, 08.00 - 09.00 h

Venue

RheinMain CongressCenter (rmcc)
Friedrich-Ebert-Allee 1
65189 Wiesbaden
Phone: +49 (0) 611 / 1729-444
veranstaltungsservice-rmcc@wicm.de

Fees (per delegate, plus VAT)

The one day ticket is available for € 690,- plus VAT, both days for € 1,380 plus VAT. It includes participation in any conference track of PharmaCongress 2023 on that day(s) and the visit of the PharmaTechnica Expo. In addition, lunch and beverages during the tracks and in breaks as well as the social event on the evening of the first congress day, 28 March is included; please mark if you would like to attend the Social Event.

The fee is payable in advance after receipt of invoice.

Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms close to the CongressCenter. You will receive a room reservation form when you have registered for the conference. Reservation should be made directly with the hotel. Early reservation is recommended.

Registration

Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

Presentations/Certificate

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.
CONCEPT HEIDELBERG
P.O.Box 10 17 64
69007 Heidelberg, Germany
Phone: +49 (0) 62 21 / 84 44-0
Fax: +49 (0) 62 21 / 84 44 34
info@concept-heidelberg.de
www.concept-heidelberg.de

For questions regarding content please contact:
Dr Robert Eicher (Operations Director) at
+49 (0) 62 21 / 84 44 12, or at
eicher@concept-heidelberg.de

For questions regarding organisation please contact:
Mr Ronny Strohwalde (Organisation Manager) at
+49 (0) 62 21 / 84 44 51, or at
strohwalde@concept-heidelberg.de